Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 224 people, all of whom received a medicine called ambrisentan. There was no comparison group. Of the 224 who started, 155 completed the trial and 69 did not finish. The trial was measuring several things over 24 and 48 weeks, including how far participants could walk in six minutes, how breathless they felt during exertion, a blood marker related to heart stress (called BNP), and their overall physical function category as rated by the World Health Organization (WHO). The reported data shows that, on average, participants walked about 20.5 metres further at 24 weeks compared to when they started. For breathlessness — measured on a 0-to-10 scale where 0 means no breathlessness and 10 means maximum — the average score changed by minus 0.5 points at 24 weeks and minus 0.6 points at 48 weeks. The BNP blood marker (a measure related to heart stress) showed a reported average decrease of 25.5% at 24 weeks and 29.2% at 48 weeks. For the WHO physical function category at 24 weeks, the reported data shows approximately 22.2% of participants improved by at least one category, 70.1% stayed the same, and 6.8% worsened. Some percentage breakdowns within those categories were reported as zero or not separately detailed in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Pulmonary Hypertension Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) caused by one of several specific conditions, including: idiopathic or familial pulmonary arterial hypertension (PAH), PAH linked to connective tissue disease, certain heart defects, HIV, certain drugs or toxins, thyroid disorders, or some blood/storage diseases; OR lung diseases such as COPD or interstitial lung disease; OR chronic blood clots in the lungs; OR sarcoidosis
- You have been on a stable dose of certain approved pulmonary hypertension or related medications (such as a prostanoid, PDE-5 inhibitor, calcium channel blocker, or statin) for at least four weeks
- You have had a right heart catheterization (a specific heart test) before the screening visit that meets the study's required results (confirm with trial site)
- If you are a woman who could become pregnant, you must have a negative pregnancy test and agree to use two reliable forms of contraception during the study and for at least four weeks after your final visit
- If you are a man, you must be informed about and show you understand the potential risks of this medication to fertility (confirm with trial site)
Who may not be able to join:
- You have previously taken part in a clinical study involving the drug ambrisentan
- You have taken bosentan or sitaxsentan (similar medications) within the four weeks before your screening visit
- Your liver enzyme levels (AST or ALT) are more than three times higher than the normal range at your screening visit
- Your lung function or heart pressure test results do not meet the specific measurements required by the study (confirm with trial site)
- You have a medical reason why you cannot take a type of medication called an endothelin receptor antagonist (confirm with trial site)
- You have had a cancer diagnosis in the past five years, other than certain minor skin cancers or early-stage cervical cancer
- You are currently pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lewis J Rubin, MD, University of California, San Diego
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline to Week 24 in 6 Minute Walk Distance (6MWD)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.